TKT and prostate carcinoma: To assess the feasibility of hON promoter–directed co-targeting gene therapy for prostate cancer, we designed a replication-deficient adenoviral vector, Ad-522E-TK, carrying the hON-522E promoter–driven herpes simplex virus TK gene.